Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate effect on serum uric acid in rheumatic and musculoskeletal diseases
ChiCTR2500096918Phase 4Not yet recruiting
- Sponsor
- Anqing City Hospital
- Start
- Feb 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of methotrexate in hyperuricemia, rheumatism and musculoskeletal condition (MSK) (2 arms), sponsored by Anqing City Hospital. Primary endpoints: Serum uric acid and Serum ADA content. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
methotrexate
03
Conditions
hyperuricemiarheumatismmusculoskeletal condition (MSK)
Beyond the preview
Go deeper on ChiCTR2500096918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096918.